Rabeprazole decreases the amount of acid produced in your stomach. It belongs to the class of drugs known as proton pump inhibitors (PPI) which works antagonistically on the pump that is involved in final step of hydrochloric acid (HCl) secretion in the stomach.
Indications: active duodenal ulcer, active benign gastric ulcer, anastomotic ulcer, symptomatic erosive or ulcerative gastroesophageal reflux disease (GERD or heartburn), GERD maintenance, Zollinger-Ellison syndrome (a tumor in the pancreas which secretes a lot of gastrin hormone taking effect on the stomach) and other pathological hypersecretory conditions involving excessive stomach acid production and eradication of Helicobacter pylori in patients with peptic ulcer disease (PUD) or acid peptic disease.
Rabeprazole is in the US FDA pregnancy catgegory B which means that it is not expected to harm an unborn baby but do not take it without talking to your doctor. It is not known whether this drug also passes into breast milk. Inform your doctor if you are breast-feeding a baby. Symptoms of overdose with rabeprazole are not known. There are no restrictions on any food, beverages or activity while taking rabeprazole, unless instructed otherwise by your doctor.
Special precautions: exclude gastric or esophageal malignancy, long-term treatment, severe hepatic dysfunction.
Adverse reactions: Most common : headache, upset stomach or diarrhea, nausea. Others: rhinitis, asthenia, flatulence, pharyngitis, vomiting, non-specific pain/back pain, dizziness, flu-like syndrome, infection, cough, constipation, insomnia. Less frequent: rash, myalgia, chest pain, dry mouth, nervousness, bronchitis, sinusitis, chills, leg cramps, UTI, arthralgia, fever. Isolated cases: anorexia, gastritis, weight gain, depression, pruritus, vision or taste disturbances, stomatitis, sweating, leukocytosis. Erythema and rarely bullous reactions (discontinue use). Thrombocytopenia, neutropenia and leukopenia (rarely). Increased hepatic enzymes. Serious side effects from rabeprazole are rare. Stop taking rabeprazole and seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives) to rabeprazole.
Drug interactions: ketoconazole (Nizoral), itraconazole (Sporanox), ampicillin (Omnipen, Principen), iron (Feosol, Mol-Iron, Fergon, Femiron), digoxin (Lanoxin, Lanoxicaps) and cyclosporine (Sandimmune, Neoral). If you are taking any of the above mentioned drugs, inform your doctor first before taking rabeprazole. You may need dosage adjustment or special monitoring of drug levels in the blood during the rabeprazole treatment.
Drugs other than those listed here may also interact with rabeprazole. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy) -3-methyl-2-pyridinyl]- methyl]sulfinyl] -1H–benzimidazole sodium salt. It has an empirical formula of C18H20N3NaO3S and a molecular weight of 381.43. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. Rabeprazole is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium. Inactive ingredients are carnauba wax, crospovidone, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium stearate, mannitol, sodium hydroxide, sodium stearyl fumarate, talc, titanium dioxide, and yellow ferric oxide as a coloring agent.
Rabeprazole has the following structural formula: